Navigation Links
New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardioversion
Date:1/5/2011

RIDGEFIELD, Conn., Jan. 5, 2011 /PRNewswire/ -- Results of a post-hoc analysis of the RE-LY® trial among patients with non-valvular atrial fibrillation (NVAF) undergoing cardioversion, a treatment to convert an abnormal heartbeat back to normal sinus rhythm, were published online on Jan. 3 in Circulation.(1)  Stroke and systemic embolism and major bleeding episodes within 30 days of the cardioversion were the major outcome measures.  The analysis reported that rates of stroke and systemic embolism and major bleeding were low and comparable to warfarin in cardioverted patients receiving Pradaxa® (dabigatran etexilate mesylate) 150mg capsules,(1) an oral anticoagulant recently approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of stroke and systemic embolism in patients with NVAF.(2)

In RE-LY, a total of 1,983 cardioversions were performed in 1,270 patients, with similar numbers in each treatment group (647 in the dabigatran 110mg* group, 672 in the PRADAXA 150mg group and 664 in the warfarin group).(1)  Rates of stroke and systemic embolism within 30 days of cardioversion were low and did not differ significantly between treatment arms (0.77%, 0.3% and 0.6%, respectively; dabigatran 110mg vs. warfarin, p=0.71; PRADAXA 150mg vs. warfarin, p=0.45),(1) though the RE-LY trial and this subgroup analysis were not powered to demonstrate statistical significance.  Similarly, major bleeding within 30 days of cardioversion was infrequent and comparable between treatment groups (1.7%, 0.6% and 0.6%, respectively).(1)

"Cardioversion is one treatment option for patients with atrial fibrillation and requires anticoagulation both prior to and following treatment in order to reduce the risk of stroke," said Rangadham Nagarakanti, MD, Louisiana State University School of Medicine.  "It's helpful to know that patients on PRADAXA who underwent cardioversion had low rates of stroke and systemic embolism
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New PLATO Sub-Analysis of CABG Patients Presented at ACC
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Data Published in The Lancet Compare Dabigatran Etexilate to Dose-Adjusted Warfarin Across RE-LY® Trial Centers
4. New Analyses of Data From RE-LY Trial, Involving Oral Anticoagulant Pradaxa, to be Presented at American Heart Associations Scientific Sessions
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Germany und LONDON ... , Ziel der Zusammenarbeit sind ... genomischer Daten aus Plasmaproben zur Steuerung von Therapien ... werden kann  Neuer Bluttest basiert auf ... und soll auf Rotor-Gene Q, einer Automationsplattform der ...
(Date:7/28/2014)... 2014 OmPrompt today announces ... help it meet the global demand for customer ... logistics. Albion joins Shackleton Ventures.      ... the past 18 months OmPrompt has underpinned accelerated ... team and its operations. The new funding will ...
(Date:7/25/2014)... N.C. , July 25, 2014  In today,s ... is costly and challenging - as is managing a ... Is it possible - or even preferable ... If so, where can you combine resources and activities, ... These are just a few of ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7OmPrompt Funded for Customer Automation Management Market Expansion 2Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2
... April 11, 2011 iCyt Mission Technology, Inc. (iCyt), ... announced the introduction of its new line of 405nm-excited ... Violet™ 421 products are part of the first commercial ... "This exciting new class of fluorescent probes will ...
... 11, 2011 Leading-edge Clinical Pharmacology and Cardiac ... announces the addition of Aziz Karim, BPharm, PhD, ... and advisor to Spaulding,s Clinical Pharmacology/Pharmacokinetic department.   ... the principles of Clinical Pharmacology and rational drug ...
Cached Medicine Technology:iCyt Unveils Exciting New Flow Cytometry Reagents Utilizing Innovative Fluorochrome Technology 2Spaulding Clinical Welcomes Dr. Aziz Karim, Clinical Pharmacokinetic Consultant 2
(Date:7/28/2014)... Amy Norton HealthDay ... Tonsillectomies are commonly done to relieve sleep apnea in children, ... kids, weight gain -- especially if they,re already overweight. ... risk factor for a range of health problems -- including, ... kids who need it. Instead, they said, doctors and ...
(Date:7/28/2014)... Lourdes Health System has partnered with ... wait times for veterans needing medical care. , Lourdes ... state—and the only one in Camden, Burlington and Gloucester ... program (PC3). PC3 gives veterans access to specialty care ... services due to lack of available specialists, long wait ...
(Date:7/28/2014)... 2014 The American Society ... professionals engaged in the field of organ transplantation, ... and Immunology Research Network (TIRN), a professional ... As modern organ transplantation continues to diversify, AST ... provide more opportunities for physicians, scientists and researchers ...
(Date:7/28/2014)... July 28, 2014 With California in ... is welcome news that a fire blanket ... protection is under development by SunSeeker Enterprises, Inc. The ... protect spacecraft from the extreme heat of re-entry into ... firefighters and homes. , “Our firefighters routinely lay their ...
(Date:7/28/2014)... Boston University School of Medicine (BUSM) report variants in ... of developing Alzheimer,s disease (AD). The discovery of this ... options that target PLXNA4 specifically. These findings appear in ... the most frequent age-related dementia affecting 5.4 million Americans ... and more than 40 percent of people age 85 ...
Breaking Medicine News(10 mins):Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 2Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 3Health News:Lourdes Expands Military Partnership with Veterans 2Health News:Lourdes Expands Military Partnership with Veterans 3Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Researchers identify potential biomarker for AD 2
... throat strictures, cancer, group warns , FRIDAY, Aug. 31 ... heartburn once a month and more than 15 million ... of Gastroenterology. , Heartburn occurs when stomach contents ... tube that connects the mouth and the stomach. , ...
... to Help Ensure Success, ANAHEIM, Calif., Aug. 31 ... coach Tim Borland,will run a full marathon each day ... to a deadly children,s disease. His "A-T CureTour" -- ... take him,across the country, ending on Nov. 4 with ...
... MTD ) today announced the webcast of its,presentation ... on Friday, September 7, 2007, at 9:10 a.m. Eastern ... the investor relations page on the,Company,s Web site at ... be,available for seven days. METTLER TOLEDO is a ...
... Kan., Aug. 31 Juergen Richt, lead,scientist with ... and an adjunct professor at Iowa State University, ... Distinguished Professor. Richt,s appointment begins in April ... the College of Veterinary,Medicine, is the most prestigious ...
... Inc. (Nasdaq: AMCS ),a leader in radiology and medical image ... investors at the,Thomas Weisel Partners Healthcare Conference 2007 being held in ... -- Thursday, September 6, 2007 ... at 8:35 a.m. (Eastern Time), ...
... shows blocking 2 proteins could mean less invasive treatment ... -- The swelling that normally occurs when a joint ... researchers say. , Publishing in the September issue of ... two immune system proteins -- interleuken-1 and tumor necrosis ...
Cached Medicine News:Health News:Heartburn Can Be a Sign of Serious Disease 2Health News:Ultra-Runner to Run 63 Marathons in 63 Days for Children with Incurable Disease 2Health News:Ultra-Runner to Run 63 Marathons in 63 Days for Children with Incurable Disease 3Health News:Ultra-Runner to Run 63 Marathons in 63 Days for Children with Incurable Disease 4Health News:Expert on Emerging Infectious Zoonotic Diseases Joining K-State as a Regents Distinguished Professor 2Health News:Expert on Emerging Infectious Zoonotic Diseases Joining K-State as a Regents Distinguished Professor 3Health News:AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007 2Health News:Swelling After Knee Injury May Hinder Healing 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: